Case Status
Case Caption
In re Vaxart, Inc. Sec. Litig.
Lead Counsel
Practice Areas
U.S. Court for the Northern District of California
Case Number
San Francisco
Vaxart, Inc.
Cezar Andrei Floroiu
Wouter W. Latour, M.D.
Steven J. Boyd
Keith Maher, M.D.
Armistice Capital LLC
Robert A. Yedid
Todd C. Davis
Michael J. Finney, Ph.D.
Sean N. Tucker
Margaret A. Echerd
Stock Symbol
File Date
Class Period
Lead Plaintiff Deadline

This is a securities fraud class action brought on behalf investors who purchased Vaxart, Inc. (“Vaxart” or the “Company”) securities between June 25, 2020 and August 19, 2020, inclusive (the “Class Period”). The action alleges claims under the federal securities laws against Vaxart, a clinical-stage vaccine developer, its senior executives, Board members, and controlling shareholder Armistice.

Commenced by Hagens Berman on August 24, 2020 after conducting an extensive investigation, the case arises from Defendants’ alleged fraudulent scheme to profit from artificially inflating the Company’s stock price by announcing false and misleading information concerning Vaxart’s oral COVID-19 vaccine candidate.  Specifically, the Complaint alleges that on June 26, 2020, Vaxart issued a press release entitled, “Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed,” falsely claiming its vaccine had been selected to participate in a non-human challenge study, organized and funded by OWS. This announcement sent the price of Vaxart shares rocketing higher.

The complaint alleges that, in furtherance of the scheme, Defendants amended controlling shareholder Armistice’s existing warrant agreements, allowing Armistice to exercise all of its warrants immediately and sell 27.6 million Vaxart shares, reaping profits of approximately $200 million. Defendants also issued millions of dollars in favorable stock options to Vaxart’s most senior executives.

On July 25, 2020, the truth emerged when The New York Times published an article entitled, “Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine,” covering suspiciously timed stock bets that had generated significant profits for senior executives and board members at companies developing vaccines and treatments. Vaxart was featured prominently in the article, and it clarified “Vaxart is not among the companies selected to receive significant financial support from Warp Speed.” In response to this news, the price of Vaxart shares dropped sharply, injuring investors.

Case Timeline
Hagens Berman is Appointed Lead Counsel.
Case Status
Lead Plaintiffs file Consolidated Amended Complaint.
Case Status


Lead Plaintiffs file Consolidated Amended Complaint.

Hagens Berman is Appointed Lead Counsel.

Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.